Advertisement

Neurological Sciences

, Volume 38, Issue 3, pp 425–431 | Cite as

Serum glutathione peroxidase, xanthine oxidase, and superoxide dismutase activities and malondialdehyde levels in patients with Parkinson’s disease

  • Burcu Gökçe ÇokalEmail author
  • Mustafa Yurtdaş
  • Selda Keskin Güler
  • Hafize Nalan Güneş
  • Ceyla Ataç Uçar
  • Bilal Aytaç
  • Zahide Esra Durak
  • Tahir Kurtuluş Yoldaş
  • İlker Durak
  • Hikmet Can Çubukçu
Original Article

Abstract

Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by loss of dopaminergic (DA) neurons in the substantia nigra pars compacta (SNpc). Oxidative stress has been hypothesized to play a major role in the development of PD in various studies. This study assessed to investigate oxidative and anti-oxidative status in PD patients. We evaluated oxidant/antioxidant status by measuring serum malondialdehyde (MDA) levels, xanthine oxidase (XO) activities, and activities of antioxidant enzymes, namely, glutathione peroxidase (GSH-Px) and superoxide dismutase (SOD). The study included 29 patients with PD and 32 healthy subjects as controls. Comparison of oxidative parameters in the patient and control groups revealed significantly higher GSH-Px and XO activities in the patient group. Serum MDA and SOD activities in PD patients were not significantly different from the controls. MDA was negatively correlated with duration of the PD and positively with age of onset. There was a negative correlation between SOD and Hoehn and Yahr (H&Y) stage. According to these results, we suggest that oxidative stress may contribute to the development of PD.

Keywords

Parkinson’s disease Oxidative stress Glutathione peroxidase Xanthine oxidase Superoxide dismutase Malondialdehyde 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflicts of interest.

Ethical approval

All procedures performed on human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants who included in the study.

References

  1. 1.
    Kalia LV, Lang AE (2015) Parkinson’s disease. Lancet 386(9996):896–912CrossRefPubMedGoogle Scholar
  2. 2.
    Blesa J, Trigo-Damas I, Quiroga-Varela A, Jackson-Lewis VR (2015) Oxidative stress and Parkinson’s disease. Front Neuroanat 8(9):91Google Scholar
  3. 3.
    Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinic–pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:181–184CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17:427–442CrossRefPubMedGoogle Scholar
  5. 5.
    Fahn S, Elton RL, Members of the UPDRS Development Committee (1987) Unified Parkinson’s Disease Rating Scale. In: Fahn S, Marsden CD, Goldstein M, Calne DB (eds) Recent Developments in Parkinson’s Disease, 2nd edn. Macmillan Health Care Information, Florham Park, pp 153–164Google Scholar
  6. 6.
    Dahle LK, Hill EG, Holman RT (1962) The thiobarbituric acid reaction and the autoxidations of polyunsaturated fatty acid methyl esters. Arch Biochem Biophys 98:53–261CrossRefGoogle Scholar
  7. 7.
    Paglia DE, Valentine WN (1967) Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med 70(1):158–169PubMedGoogle Scholar
  8. 8.
    Durak I, Canbolat O, Kavutcu M, Ozturk HS, Yurtarslani Z (1996) Activities of total, cytoplasmic, and mitochondrial superoxide dismutase enzymes in sera and pleural fluids from patients with lung cancer. J Clin Lab Anal 10(1):17–20CrossRefPubMedGoogle Scholar
  9. 9.
    Hashimato S (1974) A new spectrophotometric assay method of xanthine oxidase in crude tissue homogenate. Anal Biochem 62(2):426–435CrossRefGoogle Scholar
  10. 10.
    Neurologic Diseases in the Elderly Research Group, de Rijk MC, Launer LJ, Berger K, Breteler MM, Dartigues JF, Baldereschi M, Fratiglioni L, Lobo A, Martinez-Lage J, Trenkwalder C, Hofman A (2000) Prevalence of Parkinson’s disease in Europe: A collaborative study of population-based cohorts. Neurology 54(11 Suppl 5):S21–S23Google Scholar
  11. 11.
    Garrido M, Tereshchenko Y, Zhevtsova Z, Taschenberger G, Bahr M, Kugler S (2011) Glutathione depletion and overproduction both initiate degeneration of nigral dopaminergic neurons. Acta Neuropathol 121:475–485CrossRefPubMedGoogle Scholar
  12. 12.
    Surmeier DJ, Guzman JN, Sanchez-Padilla J, Schumacker PT (2011) The role of calcium and mitochondrial oxidant stress in the loss of substantia nigra pars compacta dopaminergic neurons in Parkinson’s disease. Neuroscience 198:221–231CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Ghezzi P, Jaquet V, Marcucci F, Schmidt HH (2016) The oxidative stress theory of disease: levels of evidence and epistemological aspects. Br J Pharmacol. doi: 10.1111/bph.13544 PubMedGoogle Scholar
  14. 14.
    Halliwell B (2012) Free radicals and antioxidants: updating a personal view. Nutr Rev 70:257–265CrossRefPubMedGoogle Scholar
  15. 15.
    Margis R, Dunand C, Teixeira FK, Margis-Pinheiro M (2008) Glutathione peroxidase family–an evolutionary overview. FEBS J 275(15):3959–3970CrossRefPubMedGoogle Scholar
  16. 16.
    Niedernhofer LJ, Daniels JS, Rouzer CA, Greene RE, Marnett LJ (2003) Malondialdehyde, a product of lipid peroxidation, is mutagenic in human cells. J Biol Chem 278(33):31426–31433CrossRefPubMedGoogle Scholar
  17. 17.
    Kostić DA, Dimitrijević DS, Stojanavić GS, Palić IR, Dordević AS, Ickovski D (2015) Xanthine oxidase: isolation, assays of activity, and inhibition. J Chem. doi: 10.1155/2015/294858 Google Scholar
  18. 18.
    Kilinç A, Yalçin AS, Yalçin D, Taga Y, Emerk K (1988) Increased erythrocyte susceptibility to lipid peroxidation in human Parkinson’s disease. Neurosci Lett 87:307–310CrossRefPubMedGoogle Scholar
  19. 19.
    Abraham S, Soundararajan CC, Vivekanandhan S, Behari M (2005) Erythrocyte antioxidant enzymes in Parkinson’s disease. Indian J Med Res 121:111PubMedGoogle Scholar
  20. 20.
    Poirier J, Barbeau A (1987) Erythrocyte antioxidant activity in human patients with Parkinson disease. Neurosci Lett 75:345–348CrossRefPubMedGoogle Scholar
  21. 21.
    Kalra J, Rajput AH, Mantha SV, Prasad K (1992) Serum antioxidant enzyme activity in Parkinson’s disease. Mol Cell Biochem 110(2):165–168CrossRefPubMedGoogle Scholar
  22. 22.
    Damier P, Hirsch EC, Zhang P, Agid Y, Javoy-Agid F (1993) Glutathione peroxidase, glial cells and Parkinson’s disease. Neuroscience 52:1–6CrossRefPubMedGoogle Scholar
  23. 23.
    Ye ZW, Zhang J, Townsend DM, Tew KD (2015) Oxidative stress, redox regulation and diseases of cellular differentiation. Biochim Biophys Acta 1850 8:1607–1621CrossRefGoogle Scholar
  24. 24.
    Obata T, Kubota S, Yamanaka Y (2001) Allopurinol supresses para-nonylphenol and 1-methyl-4-phenylpyridinium ion (MPP+ induced hydroxyl radical generation in rat striatum. Neurosci Lett 306(1–2):9–12CrossRefPubMedGoogle Scholar
  25. 25.
    Sudha K, Rao AV, Rao S, Rao A (2003) Free radical toxicity and antioxidants in Parkinson’s disease. Neurol India 51(1):60–62PubMedGoogle Scholar
  26. 26.
    Baillet A, Chanteperdrix V, Trocmé C, Casez P, Garrel C, Besson G (2010) The role of oxidative stress in amyotrophic lateral sclerosis and Parkinson’s disease. Neurochem Res 35(10):1530–1537CrossRefPubMedGoogle Scholar
  27. 27.
    Sharma A, Kaur P, Kumar B, Prabhakar S, Gill KD (2008) Plasma lipid peroxidation and antioxidant status of Parkinson’s disease patients in the Indian population. Parkinsonism Relat Disord 14(1):52–57CrossRefPubMedGoogle Scholar
  28. 28.
    Ahlskog JE, Uitti RJ, Low PA, Tyce GM, Nickander KK, Petersen RC, Kokmen E (1995) No evidence for systemic oxidant stress in Parkinson’s or Alzheimer’s disease. Mov Disord 10(5):566–573CrossRefPubMedGoogle Scholar
  29. 29.
    Bostantjopoulou S, Kyriazis G, Katsarou Z, Kiosseoglou G, Kazis A, Mentenopoulos G (1997) Superoxide dismutase activity in early and advanced Parkinson’s disease. Funct Neurol 12(2):63–68PubMedGoogle Scholar
  30. 30.
    de Farias CC, Maes M, Bonifácio KL, Bortolasci CC, de Souza Nogueira A, Brinholi FF, Matsumoto AK, do Nascimento MA, de Melo LB, Nixdorf SL, Lavado EL, Moreira EG, Barbosa DS (2016) Highly specific changes in antioxidant levels and lipid peroxidation in Parkinson’s disease and its progression: disease and staging biomarkers and new drug targets. Neurosci Lett 617:66–71CrossRefPubMedGoogle Scholar
  31. 31.
    Sanyal J, Bandyopadhyay SK, Banerjee TK, Mukherjee SC, Chakraborty DP, Ray BC, Rao VR (2009) Plasma levels of lipid peroxides in patients with Parkinson’s disease. Eur Rev Med Pharmacol Sci 13(2):129–132PubMedGoogle Scholar
  32. 32.
    Chen CM, Liu JL, Wu YR, Chen YC, Cheng HS, Cheng ML, Chiu DT (2009) Increased oxidative damage in peripheral blood correlates with severity of Parkinson’s disease. Neurobiol Dis 33(3):429–435CrossRefPubMedGoogle Scholar
  33. 33.
    Dotan Y, Lichtenberg D, Pinchuk I (2004) Lipid peroxidation cannot be used as a universal criterion of oxidative stress. Prog Lipid Res 43:200–227CrossRefPubMedGoogle Scholar
  34. 34.
    Colamartino M, Santoro M, Duranti G, Sabatini S, Ceci R, Testa A, Padua L, Cozzi R (2015) Evaluation of levodopa and carbidopa antioxidant activity in normal human lymphocytes in vitro: implication for oxidative stress in Parkinson’s disease. Neurotox Res 27(2):106–117CrossRefPubMedGoogle Scholar
  35. 35.
    Alberio T, Pippione AC, Comi C, Olgiati S, Cecconi D, Zibetti M, Lopiano L, Fasano M (2012) Dopaminergic therapies modulate the T-CELL proteome of patients with Parkinson’s disease. IUBMB Life 64(10):846–852CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Italia 2016

Authors and Affiliations

  • Burcu Gökçe Çokal
    • 1
    Email author
  • Mustafa Yurtdaş
    • 1
  • Selda Keskin Güler
    • 1
  • Hafize Nalan Güneş
    • 1
  • Ceyla Ataç Uçar
    • 1
  • Bilal Aytaç
    • 2
  • Zahide Esra Durak
    • 3
  • Tahir Kurtuluş Yoldaş
    • 1
  • İlker Durak
    • 4
  • Hikmet Can Çubukçu
    • 4
  1. 1.Department of NeurologyAnkara Education and Research HospitalAnkaraTurkey
  2. 2.Turkish Ministry of HealthDirectorate of Health ServicesAnkaraTurkey
  3. 3.The Laboratory of Turkish Public Health InstitutionAnkaraTurkey
  4. 4.Department of Medical BiochemistryAnkara University Faculty of MedicineAnkaraTurkey

Personalised recommendations